Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M14D1 plus atezolizumab versus standard-of-care therapy for first-line extensive-stage small cell lung cancer
2026-526781-24-00Phase 3Withdrawn
- Sponsor
- SystImmune Inc.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing BL-M14D1 plus Tecentriq with Standard-of-care therapy (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2026; status: withdrawn.
02
Drugs
BL-M14D1atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2026-526781-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526781-24-00.